Optimizing Epoetin Therapy in End-Stage Renal Disease: The Case for Subcutaneous Administration
- 1 August 1993
- journal article
- review article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 22 (2) , 13-22
- https://doi.org/10.1016/0272-6386(93)70177-z
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Evolution of Recombinant Human Erythropoietin Usage in Clinical Practice in the United StatesAsaio Journal, 1993
- Comparison of Subcutaneous and Intravenous Recombinant Human Erythropoietin for Anemia in Hemodialysis Patients with Significant Comorbid DiseaseAmerican Journal of Nephrology, 1992
- Treatment of the Anemia of Progressive Renal Failure with Recombinant Human ErythropoietinNew England Journal of Medicine, 1989
- PHARMACOKINETICS OF RECOMBINANT HUMAN ERYTHROPOIETIN IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSISThe Lancet, 1989
- The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietinKidney International, 1989
- Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney.Journal of Clinical Investigation, 1988
- Dynamics of erythropoiesis following renal transplantationKidney International, 1987
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986
- Isolation and characterization of the erythroid progenitor cell: CFU-E.The Journal of cell biology, 1983
- THE INCREASED DOSE‐RESPONSE OF ESF AFTER ESF STIMULATION*Annals of the New York Academy of Sciences, 1968